Molecular Signatures of Therapy: Biomarkers Predicting Response and Relapse in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: 15 July 2026 | Viewed by 564
Special Issue Editor
Interests: lncRNA-mediated transcriptional regulation; RNA–chromatin interactions; chromatin architecture; transcriptional and epigenetic regulation in cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce this Special Issue of Cancers, dedicated to advancing our understanding of how molecular biomarkers can anticipate therapeutic outcomes and forewarn disease relapse. Precision oncology increasingly depends on refined biomarkers that not only stratify patients before treatment, but also monitor residual disease, early recurrence, and evolving resistance.
This Special Issue invites original research articles and reviews that focus on:
- Predictive biomarkers: molecular signatures (genomic, transcriptomic, proteomic, epigenetic) that indicate the likelihood of response to targeted therapies, immunotherapies, or conventional modalities.
- Therapy-induced dynamics: changes in biomarker profiles during treatment (for example, via liquid biopsy, circulating tumour DNA, exosomes, immune signatures) that reflect early response, emerging resistance, or minimal residual disease.
- Mechanisms of relapse: molecular and cellular drivers of disease recurrence, including persistence of residual clones, tumour evolution under treatment pressure, microenvironmental adaptations, and immune escape.
- Strategies for relapse-prediction and monitoring: assays and models for timely detection of recurrence (biomarker-based surveillance, imaging-biomarker integration, multi-omics longitudinal profiling) and their translation into clinical protocols.
- Translational and clinical implementation: biomarker-guided clinical trials, companion diagnostics, integration of biomarkers into therapeutic decision-making and relapse prevention frameworks, and real-world evidence supporting biomarker utility.
We welcome contributions across all cancer types and therapeutic modalities and particularly encourage multi-disciplinary studies that bridge molecular discovery with clinical application. All submitted manuscripts will undergo rigorous peer review to ensure the highest scientific quality and relevance to the field.
Join us in building a timely and impactful collection that brings together biomarker science with actionable clinical insight—helping to bring the next generation of precision therapy and relapse-prevention strategies into practice.
Dr. Antonis Giakountis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- molecular biomarkers
- therapeutic response
- disease relapse
- precision oncology
- liquid biopsy
- predictive biomarkers
- multi-omics integration
- minimal residual disease
- translational oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
